EMBI - Emerald Bioscience's lead compound to enter human trials next year

Emerald Bioscience ([[EMBI]] +0.8%) says that it is highly focused on advancing its lead compound THCVHS, a THC prodrug, for glaucoma into human studies. Anticipates to initiate first in-human study in Q3 2021 with data anticipated in early 2022.It also expects to commence additional preclinical assessments of neuroprotection and comparison of THCVHS with leading glaucoma treatments.Glaucoma study will consist of a single ascending dose arm in healthy volunteers, followed by a multiple ascending dose arm in healthy volunteers, as well as assess subjects with glaucoma and/or elevated intra-ocular pressure. The company also looks to prudently advance preclinical studies for CBDVHS, an analog of CBD, to examine its utility for ocular, neurological, pain and addiction disorders.Last month, the company raised ~$7M in a registered offering of ~117 units at $0.06 per unit.

For further details see:

Emerald Bioscience's lead compound to enter human trials next year